Revitope Oncology

What Revitope Oncology does

Revitope Oncology is a privately held, preclinical-stage biotechnology company developing next-generation T cell engager immunotherapies for solid tumors. Its proprietary TwoGATE™ (also branded PrecisionGATE™) platform uses a split-paratope "AND-gate" architecture combined with a protease-activatable prodrug design, in which the CD3 T-cell engaging binding domain is split across two bispecific antibodies that must bind simultaneously to two distinct tumor antigens on the same cancer cell before immune activation occurs, and the molecules remain inactive until tumor-microenvironment proteases cleave a stabilizing domain. The lead internal candidate, REV-403 (EGFR x PDL1), targets lung cancer and other solid tumors; broader pipeline programs are licensed to or co-developed with Genmab, Junshi Biosciences, and Janssen Biotech.

The company monetizes its platform exclusively through licensing and co-development partnerships with biopharmaceutical companies rather than through direct commercialization. Revenue consists of upfront license payments, conditional equity investments, and contingent development, regulatory, and commercial milestone payments plus tiered royalties on net sales. Disclosed deal economics include up to $600M in milestones plus tiered royalties from Genmab (October 2024) and up to $160M per molecule plus royalties from Junshi (July 2020), accompanied by a $10M Junshi equity investment for a 9.99% stake. Revitope's customers are large and mid-sized biopharmaceutical companies seeking differentiated T cell engager technology, and its end-user patients are those with solid tumor cancers where conventional immunotherapy is limited by on-target, off-tumor toxicity.

Name

Revitope Oncology

Legal name

Revitope Oncology Inc.

Website

https://revitope.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Revitope Oncology is a preclinical-stage biotech developing TwoGATE™ bispecific T cell engager immunotherapies for solid tumors, monetizing its split-paratope AND-gate platform exclusively through licensing and co-development partnerships with pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Bispecific Antibody Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAAAF

Bispecific & Multispecific Antibodies

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAAAIAB

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Bispecific antibody therapy
• T cell engager immunotherapies
• Cancer immunotherapy platform
• Solid tumor therapeutics
• Antibody engineering

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Milestone Payments: Revitope earns upfront payments, development, regulatory, and commercial milestone payments, and tiered royalties on net sales from licensing its TwoGATE™ technology platform to pharmaceutical partners (e.g., Genmab up to $600M + royalties; Junshi up to $160M per molecule + royalties). Partners receive exclusive worldwide rights to develop and commercialize resulting products.
2. Equity Investment: Partners may make conditional equity investments in Revitope as part of collaboration agreements. Junshi Biosciences committed $10M for 9.99% of Revitope Oncology shares on an as-converted basis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Revitope Oncology develops and licenses its proprietary TwoGATE™ (Two-component Guided Antibody Tumor Engager) bispecific antibody platform, which uses a split-paratope AND-gate architecture combined with tumor-microenvironment protease activation to drive precision T cell engagement against solid tumors. The company advances an internal pipeline led by REV-403 (EGFR x PDL1) alongside partnered programs with Junshi Biosciences, Genmab, and Janssen, monetizing the technology through upfront payments, milestones, and royalties.

Product overview

Revitope Oncology is developing a new class of precision cancer immunotherapies based on its proprietary TwoGATE™ (also called PrecisionGATE™) Technology Platform. This platform is a modular bispecific antibody system that uses dual antigen targeting with a true AND gate mechanism to achieve tumor-specific T cell engagement. The technology splits the T-cell activating binding domain into two halves, each attached to a different tumor-targeting antibody, ensuring immune activation only occurs when both molecules bind simultaneously to cancer cells co-expressing both target antigens. The company's pipeline includes its lead candidate REV-403 (EGFR x PDL1) for solid cancers, along with undisclosed targets partnered with Genmab and Junshi Biosciences.

Differentiator

Problem solved

Functional benefit

Products and services

• TwoGATE™ Technology Platform A proprietary bispecific antibody technology platform that uses dual antigen targeting with a true AND-gate mechanism, splitting the CD3 T-cell engaging domain into halves that only recombine and activate T cells when both molecules bind simultaneously to two distinct antigens on the same cancer cell; includes protease-activatable prodrug design and half-life extension for tumor-microenvironment-controlled immune activation. Licensed to pharmaceutical partners and used internally to build Revitope's pipeline.
• REV-403 TwoGATE™ (EGFR x PDL1) Revitope's lead TwoGATE bispecific antibody candidate designed to bind EGFR and PDL1 antigens co-expressed on lung cancer cells and other solid tumor types, using the TwoGATE AND-gate architecture for precision tumor targeting and controlled T cell activation. Preclinical-stage, product rights held by Revitope.

Quantifiable outcome

• Genmab license: $9M upfront payment, up to $600M in milestones plus tiered single-digit royalties on commercial sales
• +1 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered major and minor.

• Genmab A/SmajorOEM/ Whitelabel/ Licensing Partner · 29 October 2024Revitope signed a license agreement granting Genmab exclusive rights to utilize the TwoGATE™ conditional TCE technology for multiple drug target pairs during a multi-year research period, with options for up to three exclusive worldwide development and commercialization licenses. Revitope receives $9M upfront and is eligible for up to $600M in milestone payments plus tiered single-digit royalties on commercial sales.
• Applied BioMathminorStrategic or Co-development Partner · 9 February 2021Revitope extended its collaboration with Applied BioMath to develop a systems pharmacology model for its dual antigen targeting TwoGATE™ platform for solid tumor indications. Applied BioMath will develop a semi-mechanistic systems pharmacology model to predict human efficacious dose. Previous collaborations provided valuable models for identifying optimal therapeutic parameters.
• Janssen Biotech, Inc. (Johnson & Johnson)majorStrategic or Co-development Partner · 5 January 2021Collaboration with Janssen to evaluate Revitope's PrecisionGATE T cell engager platform for developing next-generation bispecific antibody therapies. The agreement was facilitated by Johnson & Johnson Innovation. Terms of the collaboration include a feasibility study.
• Junshi BiosciencesmajorStrategic or Co-development Partner · 13 July 2020Strategic research collaboration and license agreement where Revitope leverages its TEAC platform with Junshi's novel antibody components to develop up to five TEAC molecules against tumor targets selected by Junshi. Revitope receives up to $160M in milestones per molecule plus tiered royalties. Junshi received worldwide exclusive license and has sole responsibility for IND studies, clinical development, manufacturing, and commercialization. Junshi also committed to a $10M equity investment for 9.99% of Revitope Oncology shares.
• Servier / LabCentralminorStrategic or Co-development Partner · 26 April 2018Revitope won the Golden Ticket awarded by Servier as part of its sponsorship of LabCentral, a prestigious biotech startup launchpad in Cambridge, MA. The prize is a year's residency at LabCentral's facilities for a Revitope scientist, including lab space, access to research equipment, shared infrastructure, and business coaching support.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Maverick Therapeutics: Maverick Therapeutics developed conditional T cell engagers (COBRA platform) using a prodrug-like activation mechanism to achieve tumor-specific T cell engagement, closely mirroring Revitope's TwoGATE AND-gate approach. Acquired by Takeda in 2021, representing a high-comparison comparable on both technology and exit outcome.
• Harpoon Therapeutics: Harpoon developed T cell engagers (TriTAC platform) targeting solid tumors with built-in tumor-specific activation mechanisms. Acquired by Merck in 2024, Harpoon represents a near-identical strategic profile to Revitope as a clinical-stage T cell engager platform for solid tumors.

Emerging players

• Biotheus: Biotheus is a clinical-stage biotech developing bispecific antibodies for solid tumors and immuno-oncology, with a pipeline overlapping Revitope's solid tumor TCE focus area. Direct therapeutic overlap with Revitope's indication strategy.
• Adagene: Adagene is a clinical-stage biotech using computational biology to engineer precision antibody therapeutics for oncology, with powerbody bispecific and conditional activation concepts overlapping Revitope's conditional bispecific TCE approach.
• Dragonfly Therapeutics: Dragonfly develops NK cell engagers and cytokine-based immunotherapies for oncology using a TriNKET platform with built-in tumor-targeting logic. The conditional/targeted immune engager concept closely resembles Revitope's precision immune activation thesis.
• Cullinan Oncology: Cullinan Oncology is a clinical-stage biotech developing targeted oncology therapies including bispecific antibodies for solid tumors. Comparable business model as a focused oncology therapeutics developer with multiple partnered and internal programs.
• Compass Therapeutics: Compass Therapeutics is a clinical-stage biotech developing bispecific antibodies for oncology using a proprietary platform to engineer antibodies with enhanced tumor selectivity. Direct overlap with Revitope's bispecific antibody platform business model and oncology focus.
• Atreca: Atreca developed a proprietary antibody discovery platform using single-cell sequencing to identify novel antibodies from human immune responses, with oncology as the primary therapeutic area. Comparable as an antibody platform-based biotech pursuing immuno-oncology partnerships.

Broad incumbents

• Zymeworks: Zymeworks operates Azymetric, a clinical-stage bispecific antibody platform targeting oncology and other indications. As an established bispecific platform player, Zymeworks represents the broader incumbent class that Revitope competes against in partnership-driven bispecific antibody development.
• MacroGenics: MacroGenics operates the DART platform for bispecific antibodies, including T cell engagers and immune checkpoint modulators in oncology. As a publicly-traded bispecific antibody incumbent with multiple clinical programs, MacroGenics is a broad comparator for platform-based bispecific business models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/revitope

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revitope Oncology